Pyxis Oncology announced positive updated data from its ongoing global Phase 1 monotherapy study of its lead drug candidate, micvotabart pelidotin (MICVO). The trial evaluated patients with second-line and beyond recurrent/metastatic head and neck squamous cell carcinoma (HNSCC), with data showing significant efficacy and a manageable safety profile.
Key Details
- Efficacy Results: In an efficacy-evaluable population of 33 patients, MICVO demonstrated a 36% confirmed objective response rate (cORR) and a 94% disease control rate (DCR).
- Survival Outcomes: The study reported a median progression-free survival (mPFS) of 6.2 months and a 12-month overall survival (OS) probability of 79%. All data is as of the August 18, 2026 cutoff.
- Next Steps: The positive results support the advancement of MICVO into a pivotal program, with the company planning to initiate a Phase 3 trial in mid-2027.